KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Long-Term Deferred Tax (2020 - 2025)

Pacira BioSciences (PCRX) has 6 years of Long-Term Deferred Tax data on record, last reported at $120.2 million in Q3 2025.

  • For Q3 2025, Long-Term Deferred Tax fell 10.32% year-over-year to $120.2 million; the TTM value through Sep 2025 reached $120.2 million, down 10.32%, while the annual FY2024 figure was $130.4 million, 9.77% down from the prior year.
  • Long-Term Deferred Tax reached $120.2 million in Q3 2025 per PCRX's latest filing, down from $128.3 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $169.3 million in Q1 2022 and bottomed at $93.3 million in Q3 2021.
  • Average Long-Term Deferred Tax over 5 years is $138.9 million, with a median of $141.1 million recorded in 2024.
  • Peak YoY movement for Long-Term Deferred Tax: skyrocketed 69.52% in 2022, then dropped 15.82% in 2024.
  • A 5-year view of Long-Term Deferred Tax shows it stood at $153.4 million in 2021, then rose by 4.53% to $160.3 million in 2022, then dropped by 9.87% to $144.5 million in 2023, then decreased by 9.77% to $130.4 million in 2024, then fell by 7.81% to $120.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Long-Term Deferred Tax were $120.2 million in Q3 2025, $128.3 million in Q2 2025, and $129.0 million in Q1 2025.